Building the Foundation
With the Synthetic Biology 1.0 conference, the field took a giant step forward. For the first time, practitioners gathered under one roof to share their data and dreams with each otherand with some interested parties from government and the investment community. Endy used his platform as one of the organizers and speakers to push the point that while data and good intentions are fine, the success of synthetic biology requires something more. What will be needed, he said, is a foundation built from a sturdy matrix of organizing principles, transparency, public education, and a strategy for dealing with the media, IP lawyers, investors, and entrepreneurs the field will attract. It was a bold, perhaps premature, call to arms.
Endy reasons that if youve got people like Poste talking about how important and potentially widespread synthetic biology could becomein good ways and badits time for the rest of the field to start talking about it too.
A lot of people have their heads in the sand, or up in the clouds, about this issue. I dont know if we need an Asilomar Conference, says Endy, referring to the 1975 conference where the ethics and guiding principles for working with recombinant DNA were debated and delineated, paving the way for the biotech industry as we know it. But I do know that its not too early to start talking about these things.
Endy has already backed up his lofty talk. He has agreed to help craft and coördinate efforts in the synthetic-biology community to define ethical conduct and establish guiding principles. He will report on the progress of these efforts at Synthetic Biology 2.0, which will be hosted this year by the University of California, Berkeley. He also says he is willing, if asked, to meet with schools, regulators, and even politicians to address concerns about the dangers of synthetic biology.
Synthetic biology has been around for decades. The transgenic engineering debated at Asilomar was, in a sense, a rudimentary form of synthetic biology. But it wasnt until 2003 that the field began to heat up. It was in the fall of that year that genome-sequencing maverick J. Craig Venter announced that he had produced a synthetic, self-replicating virus in just two weeks. Venter is trying to design a simple microörganism capable of consuming unnaturally large amounts of carbon dioxide. The goal: a self-replicating pollution-filtration system that never needs replacing or new sources of fuel.
Also in 2003, NASA Astrobiology Institute researchers corroborated the notion that synthetic biology might help the search for signs of life on Mars.
The same year marked the first time that an artificial genetic system constructed from a six-letter genetic alphabetthe natural genetic alphabet has only four lettersyielded a normal polymerase chain reaction, a process in which bits of DNA are copied, producing more bits of DNA that can themselves produce even more bits of DNA. This advance paves the way toward a library of artificial genes that mimic natural and engineered gene function.
For their part, Endy and colleagues have started building a library of what they call biobricks. Like most of his work, Endys library is in the public domain so that scientists and students can browse through it to see what kinds of novel biological systems they can create, either by design or by serendipity. Biobricks are prominent among the materials nudging synthetic biology toward the engineering disciplines, because they allow for a framework of standardized parts and systems.
Little wonder that the biotech industry is keeping tabs on Endy. He is certainly one of the leaders in this field who everybody wants to talk to now, says Brent Erickson, vice president of the industrial and environmental division at the Biotechnology Industry Organization, the leading trade group in the biotech field.
But Endys willingness to wrestle with the ethical and societal conundrums of synthetic biology earns as much respect as his technical accomplishments. I think a lot of scientists and industry folks say they get it, but Im not sure they know what to do about it, says John Mulligan, CEO and founder of Blue Heron Biotechnology, a firm that synthesizes genes and DNA sequences. Drew does.
Mind the gap
Indeed, few scientists have the stomach to engage the public and the media as Endy has. Ortwin Renn of the University of Stuttgart noted at last summers EuroScience Open Forum in Stockholm, Sweden, that scientists are often deeply scornful of those who do. They view it as a PR stunt, he says.
Endy says that a well-respected professor approached him after the Synthetic Biology 1.0 conference, wondering whether researchers were shooting ourselves in the foot by raising concerns prematurely. After all, synthetic biologists were still far from creating any potentially harmful applications, and discussing what to do about them could set off false alarms.
Reflecting on the encounter, Endy shrugs. What people need to understand is that we dont have the answers to some key questions, like, What are the most useful and beneficial applications? Who is going to control the IP? Who is going to make sure it is not abused? How do we even begin to start educating the public about the risks and rewards?
If there are answers to these questions, Drew Endy aims to find them. I really want to see how far this field can go, he says. The answer is Not very far if we cant figure out how to get from here to there.